A phase II trial of the pan-class I PI3K inhibitor copanlisib demonstrated that it induces objective responses in 59% of patients with relapsed or refractory indolent lymphoma. The responses lasted a median of 22.6 months. Although the drugs weren't compared head to head, researchers suspect that the side effects of copanlisib may be less severe than those of idelalisib, another PI3K inhibitor.
from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2ApDJFA
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου